Agreement calls for the Centre de Pharmacologie Clinique et d'Evaluation Therapeutiques of Marseilles, France "to conduct clinical trials on up to nine products" being developed by Genta or Genta/Jago, a joint venture with Jagotec A, Genta says in May 6 release. Genta estimates that 68% of the cost of trials could be picked up by the French government, a value of up to $10 mil. The collaboration will focus on dermatologic, Anticode and Geomatrix- based drugs. The first study will be a Phase I trial of Genta's G-301, a topical formulation of methotrexate for severe psoriasis.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth